Z-Endoxifen is widely regarded as the most active metabolite of tamoxifen, and has recently demonstrated a 26.3% clinical benefit in a phase I clinical trial to treat metastatic breast cancer after the failure of standard endocrine therapy. Future pharmacological and pre-clinical studies of Z-endoxifen would benefit from reliable and efficient synthetic access to the drug. Here, we describe a short and efficient, stereoselective synthesis of Z-endoxifen capable of delivering multi-gram (37 g) quantities of the drug in >97% purity with a Z/E ratio >99% after trituration.
Keywords: Antiestrogens; Endoxifen; MHJBZVSGOZTKRH-IZHYLOQSSA-N; Nuclear receptors; Stereoselective synthesis; Tamoxifen analogs.
Copyright © 2018. Published by Elsevier Ltd.